Acumen Pharma Reports Positive Trial Results Of ACU193 In Early Alzheimer’s Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheime
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-518595670-91421a5730064d22b00fb052e694fdc8.jpg "<div>A Beginners' Guide to Managing Your Money</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2150743060-75c2828f7a4a4e13bf6af0d58576e290.jpg "How Starbucks Makes Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2171005642-7096eac42418434eafc1b341520fbe44.jpg "3 Reasons Why Retiring in Texas Might Be Your Best Financial Move")
:max_bytes(150000):strip_icc():format(jpeg)/Clipboard01-ec903bd312d74f6fb9beba1acc310125.png "How the PayPal Mafia Looks Set To Dominate the New Administration")